Ecuador ARCSA Medical Device Register Analysis: 326,334 Records

A data-driven teardown of Ecuador's ARCSA medical device registro sanitario: 326,334 listed records, 22,056 registrations, risk classes I-IV, device types, and titular concentration.

Ecuador ARCSA Medical Device Register Teardown

Ecuador's medical device market is regulated by the Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA), and every device that is not freely commercializable must hold a registro sanitario (sanitary registration) listed in ARCSA's public database. In 2026, Ecuador substantially overhauled that framework with Resolution ARCSA-DE-2026-003-DASP, adopting a four-tier IMDRF-aligned risk classification and a simplified pathway for devices already cleared by high-vigilance agencies. That reform has put Ecuador back on the LATAM filing map — which makes a clear, quantitative read of what the register actually contains especially valuable for manufacturers sequencing their 2026–2027 regional filings.

A teardown of the ARCSA medical device registro sanitario database (snapshot compiled on June 21, 2026) reveals a market that is far larger at the listed-product level than its headline registration figures suggest — and one that skews toward higher-risk, invasive product:

Total Listed Product Records: 326,334 individual product records in the database.
Unique Sanitary Registrations: 22,056 unique registro sanitario numbers — meaning the 326,334 listed records collapse into roughly 22,000 actual registrations, a ~15× ratio driven by multi-product registrations bundling many references under one number.
Unique Titular Holders: 2,238 unique titular holders (the legal entities that own the registrations).
Unique Product Brands: 6,881 unique product brands (marca_de_producto).
Risk-Class Distribution: Risk Class III is the largest class at 107,268 records, ahead of Class I at 73,060, Class II at 71,943, and Class IV at 15,038 (under the IMDRF-aligned I–IV scheme).
Device-Type Mix: Invasive devices dominate at 204,696 records, followed by In Vitro Diagnostics at 40,443, active devices at 22,764, and non-invasive devices at 19,332.
Titular Concentration: SIMED S.A. leads with 11,046 records (3.4%), followed by Ortopedia Médica ORMEDIC (9,431), TRAUMA ORTOPEDICS S.C.C. (9,400), and REGULATEC Cía. Ltda. (8,440); the top five titulares together hold 46,159 records (14.1%).
Inactive Listings: Approximately 13,826 records carry a cancellation date (fecha_cancelacion), a material share of inactive or superseded listings that headline counts overstate.

This teardown sizes the Ecuadorian market, distinguishes listed-product volume from actual registrations, maps the risk-class and device-type structure, and quantifies titular concentration. For regional context, it pairs with our Colombia INVIMA importer and apoderado concentration analysis and our El Salvador DNM medical device registry analysis.

Methodology note: This analysis is based on a compiled snapshot of the ARCSA medical device registro sanitario database dated June 21, 2026. Counts are computed directly from that public database extract by MedDeviceGuide. An important distinction: ARCSA lists products at the reference level, so one registro sanitario can cover many product references — which is why the 326,334 listed records map to only 22,056 unique registrations. Risk-class and device-type figures reflect the labeled records; absolute counts describe the snapshot, while proportional splits are the more durable takeaways.

Ecuador's Regulatory Framework: ARCSA and the 2026 Resolution

ARCSA is Ecuador's national authority for the regulation, technical control, and health surveillance of medical devices, biochemical and diagnostic reagents, and related products. The legal basis historically comprised the Health Law, Executive Decree No. 1583 (2001), and successive technical regulations, most recently Resolution ARCSA-DE-2026-003-DASP. Under that resolution, signed April 28, 2026 and published in the Registro Oficial on May 18, 2026, Ecuador replaced its decade-old device framework with three consequential changes.

First, the resolution adopts a four-tier risk classification (Classes I, II, III, IV) aligned to IMDRF principles, with classification rules for medical devices and a separate rule set for IVDs (SaMD is classified under the IMDRF/N12 matrix). Second, it introduces a simplified registration pathway: under Articles 31 and 32, ARCSA will recognize a registro sanitario (or equivalent) granted by a high-vigilance IMDRF-member agency — such as the FDA, EMA, Health Canada, TGA, or ANVISA — provided the device is classified as Risk I–IV by ARCSA and the application covers no more than 100 references (50 for Class IV). Third, the registro sanitario is valid for five years and renewable, and establishments handling storage, distribution, and transport must hold the corresponding good-practices certification. Low-risk devices remain freely commercializable subject to baseline sanitary requirements.

For manufacturers, the simplified pathway is the strategically important change: a device already cleared by an IMDRF-aligned agency can now use that clearance as the foundation of an ARCSA submission, materially compressing time-to-market and making Ecuador a viable second- or third-wave LATAM filing rather than a standalone effort — particularly for Class I and II devices.

Reading the simplified pathway operationally

The resolution's recognition mechanism comes with concrete operational limits that shape filing strategy. Recognition under Article 31 applies to clearances from agencies that are both high-vigilance and IMDRF members, and the simplified procedure under Article 32 requires that the device be classified as ARCSA Risk I–IV and be commercially marketed in IMDRF Management Committee member countries. A single simplified inscription is capped at 100 references for medical devices (DMI, DMNI, DMA) and 50 references for Class IV (DMDIV), and sets or kits can be grouped under one registro sanitario if they share a manufacturer and are used exclusively together, taking the highest-risk member's class and the shortest-shelf-life member's expiry. Establishments that store, distribute, or transport devices must now hold the corresponding good-practices certification, and SaMD is classified using the IMDRF/N12 risk matrix. The net effect is that the simplified pathway reduces documentary review for eligible devices but does not eliminate the local establishment, titular, and good-practices obligations — so partner and facility readiness, not the filing itself, often becomes the binding timeline constraint.

How large is the Ecuador ARCSA database, and how many registrations and titulares does it contain?

The ARCSA database lists 326,334 product records — but this headline figure requires careful interpretation, because it is a listed-product count, not a registration count. Those 326,334 records map to only 22,056 unique sanitary registrations, held by 2,238 unique titular holders across 6,881 product brands.

The ~15× ratio between listed records and unique registrations exists because a single registro sanitario can cover a large family of product references from the same manufacturer — for example, a test-kit system with dozens of reagent references, or an implant line with multiple sizes. This has two implications for market intelligence. First, competitor counts based on raw record numbers will overstate the number of distinct registrations by roughly an order of magnitude; benchmarking should use unique registro sanitario counts, not product-reference counts. Second, it means ARCSA's database is structurally heavy on multi-reference IVD and implant families, where one registration bundles many Stock-Keeping Units. Additionally, roughly 13,826 records carry a cancellation date, so even the listed-product count somewhat overstates the truly active market — a manufacturer should filter on validity status before drawing competitive conclusions.

How are registered devices distributed across ARCSA risk classes I to IV?

Under the IMDRF-aligned four-class scheme, the risk-class distribution among labeled records is:

Risk Class	Records	Share of Classified
Class III	107,268	40.1%
Class I	73,060	27.3%
Class II	71,943	26.9%
Class IV	15,038	5.6%

The headline finding is that Class III is the single largest risk class, at 107,268 records — roughly 40% of classified records. This is unusual: in many national registers the largest class is the lowest-risk tier (Class I or its equivalent). Ecuador's register skews toward higher-risk implantable and invasive product, which reflects both the orthopedic and trauma concentration in the titular layer (see below) and the bundling of multi-reference implant families under single registrations. Class I (73,060) and Class II (71,943) are closely matched in the middle tier, while Class IV (15,038) — the highest-risk, critical devices — is the smallest class. (A small subset of records carries numeric risk labels rather than Roman numerals; the figures above use the standard ARCSA I–IV labels.)

For market-entry planning, the Class III weight matters: it signals that the competitive and documentary burden for medium-high-risk devices (implants, sustained-use instruments, some active devices) is substantial, and that the simplified IMDRF-recognition pathway — most useful for Class I and II — will not by itself address the largest segment of the register.

Which device types (invasive, IVD, active, non-invasive) dominate the Ecuadorian register?

Normalizing the device-type field (stripping internal code prefixes) yields a clear hierarchy:

Device Type	Records
Invasive devices (Invasivo)	204,696
In Vitro Diagnostics (Diagnóstico In Vitro)	40,443
Active devices (Activo)	22,764
Non-invasive devices (No Invasivo)	19,332

Invasive devices dominate at 204,696 records — roughly 63% of all records with a device-type label. This is consistent with the Class III concentration: invasive surgical, orthopedic, and trauma products form the backbone of the register. In Vitro Diagnostics (40,443) is the second-largest type, reflecting Ecuador's diagnostic reagent and test-kit volume (and the multi-reference bundling typical of IVD families). Active devices (22,764) and non-invasive devices (19,332) form a much smaller tail. A manufacturer of invasive or orthopedic products should therefore expect a crowded, specialized competitive field, while active-device and non-invasive entrants face a comparatively thinner segment.

Who are the leading sanitary-registration titulares, and how concentrated are they?

Ranking the titular_registro_sanitario field shows that the titular layer is meaningfully concentrated in orthopedic, trauma, and regulatory-representation firms:

Titular Holder	Records	Share
SIMED S.A.	11,046	3.4%
Ortopedia Médica ORMEDIC Cía. Ltda.	9,431	2.9%
TRAUMA ORTOPEDICS S.C.C.	9,400	2.9%
REGULATEC Cía. Ltda.	8,440	2.6%
CREINECUADOR Cía. Ltda.	7,842	2.4%

SIMED S.A. leads with 11,046 records (3.4%), and the top five titulares together hold 46,159 records, or 14.1% of all listed records. Two structural points stand out. First, the top of the titular table is dominated by orthopedic and trauma distributors (ORMEDIC, TRAUMA ORTOPEDICS) and by regulatory-representation firms (REGULATEC, CREINECUADOR) — which directly mirrors the invasive-device and Class III concentration identified above. Ecuador's higher-risk segment is mediated through a recognizable group of specialized local entities. Second, with 2,238 total titulares, the layer is broad at the base but top-heavy: 14.1% in the top five is moderate concentration by global standards, but it is concentrated in the segments that matter most (orthopedics, trauma, regulatory representation).

For manufacturers, the practical implication is that market entry is gated as much by securing a capable titular with the right therapeutic footprint as by the registro sanitario filing itself — particularly for invasive and Class III products, where the established titulares already hold disproportionate share. (This full-register titular analysis is distinct from our companion piece on expired ARCSA licenses and Resolution 2026-003, which analyzes cancellation and renewal risk specifically.)

Class III titulares: who owns the high-risk segment

Because Class III is the largest risk class in Ecuador, the titular concentration within that class is especially decision-relevant. The leading Class III titulares are DISORTHO INTERNACIONAL Cía. Ltda. (3,978 records), TRAUMA ORTOPEDICS S.C.C. (3,806), CREINECUADOR Cía. Ltda. (3,707), ULBAGAR Consultoría y Representaciones Cía. Ltda. (3,649), and REGULATEC Cía. Ltda. (3,612). This is almost entirely an orthopedic, trauma, and regulatory-representation roster — confirming that Ecuador's high-risk segment is structurally mediated by a tight group of specialized local entities, several of which are pure regulatory-representation firms rather than product distributors.

The titular concentration curve

Across all 2,238 titular holders:

11 titulares cover 25% of all listed records.
34 titulares cover 50%.
76 titulares hold 1,000 or more records each.

So while the titular base is broad (2,238 entities), a quarter of the entire register sits with just 11 firms, and half with 34. The market is top-heavy in the segments that matter most, and the realistic shortlist for a manufacturer seeking an established, high-volume titular is measured in the dozens, not the hundreds.

What does the renewal pipeline look like?

The fecha_de_vigencia_del_registro_sanitario field (registro sanitario validity/expiry) reveals an unusually large renewal wave approaching — a direct operational consequence of the five-year validity rule combined with heavy historical issuance. The expiry distribution is:

Vigencia (Expiry) Year	Records
2028	69,208
2030	60,359
2029	58,611
2026	47,853
2027	37,566

Roughly 47,853 records reach expiry in 2026 alone, with the largest waves due in 2028 (69,208), 2030 (60,359), and 2029 (58,611). Across 2026–2030, well over a quarter of a million records will require renewal — and under Resolution ARCSA-DE-2026-003-DASP, renewals must comply with the new IMDRF-aligned classification and the updated documentary requirements. This is the single most important operational planning fact in the Ecuadorian register: incumbent manufacturers and their titulares face a concentrated, multi-year renewal workload, and the resolution's transition rules will determine how smoothly that workload converts into renewed (rather than lapsed) registrations.

Issuance history: where the volume came from

The issuance (fecha_de_emision) trend explains the upcoming renewal wave. The heaviest issuance years are 2020 (36,672 records), 2023 (35,859), 2024 (34,406), 2021 (30,416), and 2018 (24,880), with 23,747 in 2025. The 2018 and 2020 cohorts, now five-plus years old, are precisely the records driving the 2026–2028 vigencia expiry spike. A manufacturer benchmarking competitor activity should note that the 2023–2024 surge (70,000+ records combined) reflects both genuine market expansion and the regulatory run-up to the 2026 framework change.

Strategic Implications for Market Entry

The data supports four concrete decisions for manufacturers evaluating Ecuador in the post-2026-003 environment:

Benchmark with unique registrations, not listed-product counts. The 326,334 figure overstates the market by ~15×; use the 22,056 unique registro sanitario count (and filter out cancelled records) when sizing competitors or planning entry.
Use the simplified IMDRF pathway where eligible. Devices cleared by FDA, EMA, Health Canada, TGA, or ANVISA can now leverage that clearance for a faster ARCSA filing (up to 100 references, 50 for Class IV). Sequence Ecuador as a second- or third-wave LATAM filing rather than a standalone effort — strongest benefit for Class I and II.
Plan for a Class III-heavy, invasive competitive field. Class III is the largest risk class (107,268 records) and invasive devices are 63% of typed records. Entrants in orthopedics, trauma, and invasive surgery should expect established titular incumbents (SIMED, ORMEDIC, TRAUMA ORTOPEDICS) and budget for differentiation.
Select a titular with the right therapeutic and regulatory footprint. Because the titular layer is concentrated in specific segments, the choice of titular materially shapes competitive access — particularly for higher-risk products. Match the titular's existing portfolio and regulatory-representation capability to your device class.

How does Ecuador compare to its Andean and LATAM neighbors?

Ecuador's ARCSA database is large even by LATAM standards when measured at the listed-product level. Its 326,334 listed product records — mapping to 22,056 unique sanitary registrations — exceed the headline registration counts of several peer markets in the region, and its risk-class profile is unusual: Class III is the single largest class, whereas in many national registers the lowest-risk tier dominates. This Class III weight, combined with invasive devices forming 63% of typed records, makes Ecuador structurally an orthopedic-, trauma-, and invasive-surgery-heavy market — a profile closer to a specialized implant market than a general consumables market.

Two further features distinguish Ecuador from neighbors like Colombia (INVIMA) and El Salvador (DNM). First, the titular layer is concentrated in specialized orthopedic and regulatory-representation firms (SIMED, ORMEDIC, TRAUMA ORTOPEDICS, DISORTHO, REGULATEC, CREINECUADOR), several of which are pure regulatory-representation entities rather than product distributors — so the choice of titular in Ecuador is often a choice of regulatory-agent capability as much as commercial channel. Second, the 2026 Resolution ARCSA-DE-2026-003-DASP and its simplified IMDRF-recognition pathway have materially changed Ecuador's strategic position: a device already cleared by an IMDRF-aligned agency can now leverage that clearance, making Ecuador a credible second-wave filing rather than the standalone, document-heavy effort it was under the prior decade-old framework. For manufacturers sequencing Andean filings, that makes Ecuador worth re-evaluating alongside Colombia rather than deferring indefinitely.

Frequently Asked Questions

Which agency issues medical device sanitary registration in Ecuador?

The Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA) issues the registro sanitario for medical devices and regulates their technical control and health surveillance, under the framework replaced by Resolution ARCSA-DE-2026-003-DASP.

How many medical device sanitary registrations are listed in the ARCSA database?

The database lists 326,334 product records, but these map to 22,056 unique sanitary registrations held by 2,238 titular holders across 6,881 brands. The listed-product count is roughly 15× the unique-registration count because one registration can bundle many product references.

What risk-classification system does Ecuador use?

Under Resolution ARCSA-DE-2026-003-DASP, Ecuador uses a four-tier IMDRF-aligned scheme (Classes I, II, III, IV). In the current register, Class III is the largest class (107,268 records), followed by Class I (73,060), Class II (71,943), and Class IV (15,038).

Does Ecuador recognize foreign approvals?

Yes. Under Articles 31–32 of the resolution, ARCSA recognizes registros sanitarios or equivalents from high-vigilance IMDRF-member agencies (FDA, EMA, Health Canada, TGA, ANVISA, among others) via a simplified pathway, subject to ARCSA risk classification and reference-count limits.

How long is an Ecuadorian registro sanitario valid?

The registro sanitario is valid for five years, renewable for equal periods, under the current resolution.

Is there a renewal wave approaching in Ecuador?

Yes, a large one. Roughly 47,853 records reach vigencia expiry in 2026, with the largest waves due in 2028 (69,208), 2030 (60,359), and 2029 (58,611) — driven by heavy 2018 and 2020 issuance cohorts now reaching the end of their five-year validity. Incumbents and their titulares face a concentrated multi-year renewal workload under the new resolution's rules.

Why is Class III the largest risk class in Ecuador?

Class III (107,268 records) leads because the register is structurally weighted toward invasive, implantable, and trauma/orthopedic product, much of it registered in multi-reference families under single registros sanitarios. The top Class III titulares (DISORTHO, TRAUMA ORTOPEDICS, CREINECUADOR, ULBAGAR, REGULATEC) confirm this orthopedic-and-regulatory-representation concentration.

Conclusion

Ecuador's ARCSA database is far larger at the listed-product level than its regional peers' headline figures suggest — 326,334 product records — but those collapse into roughly 22,000 actual registrations held by about 2,200 titulares. The register skews toward higher-risk invasive product (Class III is the single largest risk class; invasive devices are 63% of typed records), and the titular layer is concentrated in orthopedic, trauma, and regulatory-representation firms. Combined with the 2026 simplified IMDRF-recognition pathway, the practical takeaway is that Ecuador is now a credible second-wave LATAM filing for eligible devices, but market entry remains gated by titular selection in the segments that dominate the register.

This article is educational and is not legal, regulatory, or commercial advice for any specific product or company. Regulations and fees change; verify current requirements directly with ARCSA before acting.

Sources

ARCSA — Dispositivos Médicos, Productos Dentales y Reactivos Bioquímicos de Diagnóstico (official): Agencia Nacional de Regulación, Control y Vigilancia Sanitaria, Government of Ecuador, controlsanitario.gob.ec.
ARCSA — Inscripción de Registro Sanitario de Dispositivos Médicos (official): Government of Ecuador, gob.ec/arcsa.
Resolution ARCSA-DE-2026-003-DASP — Normativa Técnica Sanitaria Sustitutiva (official PDF): ARCSA, Government of Ecuador, controlsanitario.gob.ec (four-tier IMDRF risk classification, simplified recognition pathway under Articles 31–32, five-year validity).
Medical device registration in Ecuador — a brief guide (consultancy): MDRC Consulting, mdrc-consulting.com.
Ecuador Medical Device Registration (consultancy): OMC Medical, omcmedical.com.
Medical device regulations with the new ARCSA resolution (consultancy): OlarteMoure, olartemoure.com.
Register data (dataset): MedDeviceGuide analysis of the ARCSA medical device registro sanitario public database extract, snapshot dated June 21, 2026.